Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Stopped early · Phase 1/Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving clofarabine together with rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine when given together with rituximab and to see how well they work in treating patients with relapsed B-cell non-Hodgkin lymphoma.
Key facts
- Study ID
- NCT00691652
- Run by
- OHSU Knight Cancer Institute
- People needed
- 2
- Starts
- 2008-05-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2019-11-27
Who can join
Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Knight Cancer Institute at Oregon Health and Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.